Weigao Medical Shareholders Approve Key Transaction Documents at Extraordinary Meeting

Shandong Weigao Group Medical Polymer Co ( (HK:1066) ) has provided an update.

Shandong Weigao Group Medical Polymer Company Limited has announced that its first extraordinary general meeting of 2026, held on 12 February in Hong Kong, duly approved an ordinary resolution by poll. Shareholders voted in favour of a series of transaction documents, including a sale and purchase agreement, a compensation agreement, and non‑competition undertakings, with approximately 88.98% of votes cast supporting the deal and 11.02% against.

The approval authorises any one director to take all necessary actions and sign documents to implement the transaction arrangements, clearing a key corporate governance hurdle for the proposed deals. Certain major shareholders and directors, including Weigao Holding, Mr. Chen Lin, and grantees under the 2014 Share Award Scheme, abstained from voting in line with regulatory and conflict‑of‑interest requirements, underscoring the company’s adherence to Hong Kong listing rules and related‑party transaction safeguards.

The most recent analyst rating on (HK:1066) stock is a Hold with a HK$5.50 price target. To see the full list of analyst forecasts on Shandong Weigao Group Medical Polymer Co stock, see the HK:1066 Stock Forecast page.

More about Shandong Weigao Group Medical Polymer Co

Shandong Weigao Group Medical Polymer Company Limited is a medical device manufacturer based in the People’s Republic of China. The company focuses on medical polymer products and related healthcare supplies, serving hospitals and healthcare providers in domestic and international markets.

Average Trading Volume: 14,288,319

Technical Sentiment Signal: Sell

Current Market Cap: HK$23.88B

Find detailed analytics on 1066 stock on TipRanks’ Stock Analysis page.